Important Information for Intellia Therapeutics, Inc. (NTLA) Investors: Rosen Law Firm Reminds of Lead Plaintiff Deadline
New York, NY – Rosen Law Firm, a global investor rights law firm, is reminding purchasers of securities of Intellia Therapeutics, Inc. (NASDAQ: NTLA) between July 30, 2024 and January 8, 2025, both dates inclusive (the “Class Period”), of the important April 14, 2025 lead plaintiff deadline. Investors who purchased Intellia securities during the Class Period may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement.
What is the Issue?
The lawsuit alleges that Intellia Therapeutics and certain of its officers and directors made false and/or misleading statements and/or failed to disclose that:
- The clinical data for Intellia’s CRISPR/Cas9 gene-editing therapy for transthyretin-mediated amyloidosis was flawed;
- The clinical data for Intellia’s CRISPR/Cas9 gene-editing therapy for beta-thalassemia was also flawed;
- The Company’s collaboration with Novartis AG was not progressing as expected;
- The Company was experiencing manufacturing issues with its CRISPR/Cas9 gene-editing therapy.
What Does This Mean for Me?
If you purchased Intellia securities during the Class Period, you may be able to recover your losses, plus a penalty for the damages you incurred. The lead plaintiff, the person who will represent the interests of all class members in this litigation, has until April 14, 2025, to apply to be certified as the lead plaintiff. The lead plaintiff will then have the ability to make important decisions in this litigation, including whether to accept a settlement or proceed to trial.
What Does This Mean for the World?
The lawsuit against Intellia Therapeutics is a reminder of the importance of transparency and accuracy in the pharmaceutical industry. The allegations of flawed clinical data and manufacturing issues could potentially delay the development and approval of Intellia’s gene-editing therapies, which have the potential to revolutionize the treatment of genetic diseases. The outcome of this litigation could also set a precedent for other gene-editing companies and could impact investor confidence in the industry as a whole.
Conclusion
If you purchased Intellia Therapeutics securities between July 30, 2024, and January 8, 2025, and believe that you have suffered a loss as a result, you may be entitled to compensation. The lead plaintiff deadline is approaching, so it is important to act quickly. Contact Rosen Law Firm today to discuss your options and protect your investor rights.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. The firm was Ranked No. 1 in the number of securities class action settlements in 2019 and 2020 according to Institutional Shareholder Services’ Securities Class Action Services.
For more information, please visit
* Rosen Law Firm accepts cases on a contingency fee basis, which means there are no upfront costs or fees for our services.
